Kyle Piskel, Chief Financial Officer at Adaptive Biotechnologies Corp (ADPT), sold 162,820 shares at $19.50 ($3.2M) on 2025-11-28, disclosed to the SEC on 2025-12-02.
Scheduled sale ($3.2M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ADPT | SELL | 2026-02-06 | $40K | — | Filing → |
| ADPT | SELL | 2026-01-14 | $77K | — | Filing → |
| ADPT | SELL | 2025-11-18 | $3K | — | Filing → |